- Home
- BDRX vs GLMD Comparison
BDRX vs GLMD Comparison
Compare BDRX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- GLMD
- Stock Information
- Founded
- BDRX 2000
- GLMD 2000
- Country
- BDRX United Kingdom
- GLMD Israel
- Employees
- BDRX N/A
- GLMD N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- GLMD Health Care
- Exchange
- BDRX Nasdaq
- GLMD Nasdaq
- Market Cap
- BDRX 3.7M
- GLMD 3.0M
- IPO Year
- BDRX N/A
- GLMD 2014
- Fundamental
- Price
- BDRX $1.55
- GLMD $1.57
- Analyst Decision
- BDRX
- GLMD Hold
- Analyst Count
- BDRX 0
- GLMD 1
- Target Price
- BDRX N/A
- GLMD N/A
- AVG Volume (30 Days)
- BDRX 1.2M
- GLMD 105.5K
- Earning Date
- BDRX 05-02-2025
- GLMD 05-29-2025
- Dividend Yield
- BDRX N/A
- GLMD N/A
- EPS Growth
- BDRX N/A
- GLMD N/A
- EPS
- BDRX N/A
- GLMD N/A
- Revenue
- BDRX N/A
- GLMD N/A
- Revenue This Year
- BDRX N/A
- GLMD N/A
- Revenue Next Year
- BDRX N/A
- GLMD N/A
- P/E Ratio
- BDRX N/A
- GLMD N/A
- Revenue Growth
- BDRX N/A
- GLMD N/A
- 52 Week Low
- BDRX $1.14
- GLMD $1.21
- 52 Week High
- BDRX $74.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- BDRX 43.94
- GLMD 48.70
- Support Level
- BDRX $1.24
- GLMD $1.30
- Resistance Level
- BDRX $1.52
- GLMD $1.67
- Average True Range (ATR)
- BDRX 0.20
- GLMD 0.14
- MACD
- BDRX 0.07
- GLMD 0.06
- Stochastic Oscillator
- BDRX 49.21
- GLMD 78.77
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.